氯氮平联合多巴丝肼片治疗帕金森病伴精神障碍60例临床观察

Clinical Observation on Clozapine Combined with Benserazide Tablets for Treating Parkinson's Disease Complicated with Mental Disorders in 60 Cases

目的观察氯氮平联合多巴丝肼片治疗帕金森病伴精神障碍的临床疗效。方法选取2015年11月至2017年11月收治的帕金森病伴精神障碍患者119例,按随机数字表法分为对照组(59例)和观察组(60例),对照组患者给予奥氮平联合多巴丝肼片治疗,观察组患者给予氯氮平联合多巴丝肼片治疗。结果治疗2,4周后,观察组患者的统一帕金森病评定量表第三部分(UPDRSⅢ)评分为(25.08±3.70)分、(20.02±2.22)分,一般精神病理量表评分为(57.21±2.54)分、(18.45±2.35)分,阳性症状量表评分为(19.06±2.80)分、(9.12±2.17)分,阴性症状量表评分为(13.02±2.62)分、(8.08±2.06)分,阳性和阴性症状量表(PANSS)总分为(91.73±1.88)分、(36.22±1.72)分,显著低于对照组同时点的(32.40±3.40)分,(34.60±2.11)分,(62.62±3.48)分,(22.78±2.82)分,(23.81±3.41)分,(11.76±2.25)分,(15.83±2.34)分,(11.90±3.04)分,(102.42±3.12)分,(47.20±2.79)分(P<0.05);观察组与对照组的不良事件发生率相当(13.33%比15.25%,P>0.05)。结论氯氮平联合多巴丝肼片治疗帕金森病伴精神障碍效果显著,能有效改善患者的运动功能、精神状态,且安全性较高,值得推广。

Objective To observe the clinical effect of clozapine combined with Benserazide Tablets in the treatment of Parkinson’s disease complicated with mental disorders. Methods Totally 119 patients with Parkinson’s disease complicated with mental disorders admitted to our hospital from November 2015 to November 2017 were selected and divided into the control group（ n = 59） and the observation group（ n = 60） according to the random number table method. The control group was given olanzapine combined with Benserazide Tablets,and the observation group was treated with clozapine combined with Benserazide Tablets. Results After 2,4 weeks of treatment,in the observation group,the scores of UPDRS Ⅲ were（ 25. 08 ± 3. 70） points and（ 20. 02 ± 2. 22） points,the scores of general psychopathological scale were（ 57. 21 ± 2. 54） points and（ 18. 45 ± 2. 35） points,the scores of positive symptoms scale were（ 19. 06 ±2. 80） points and（ 9. 12 ± 2. 17） points,the scores of negative symptoms scale were（ 13. 02 ± 2. 62） points and（ 8. 08 ± 2. 06） points,the total scores of PANSS were（ 91. 73 ± 1. 88） points and（ 36. 22 ± 1. 72） points,which were significantly lower than those of the control group with the scores of UPDRS Ⅲ [（ 32. 40 ± 3. 40） points and（ 34. 60 ± 2. 11） points ],scores of general psychopathological scale [（ 62. 62 ± 3. 48） points and（ 22. 78 ± 2. 82） points ],scores of positive symptom scale [（ 23. 81 ± 3. 41） points and（ 11. 76 ±2. 25） points ],scores of negative symptom scale [（ 15. 83 ± 2. 34） points and（ 11. 90 ± 3. 04） points ],total scores of PANSS [（ 102. 42 ±3. 12） points and（ 47. 20 ± 2. 79） points ]（ P 〈 0. 05）. The incidence rate of adverse events was similar between the observation group and the control group（ 13. 33% vs. 15. 25%,P 〉 0. 05）. Conclusion Clozapine combined with Benserazide Tablets in the treatment of Parkinson’s disease complicated with mental disorders has a significant effect,it can effectively improve the motor function and mental status of patients. It has higher safety and is worthy of promotion.